Paris-based Cardiawave, a focused ultrasound company with a mission to reduce aortic valve stenosis caused by calcification, will soon begin clinical trials to test its Valvopulse device.

Cardiawave heart 300As announced last month, the company seeks to enroll 10 patients in France, the Netherlands, and Serbia during the summer of 2019. Participating hospitals in the multicenter, international study are Georges Pompidou European Hospital in Paris, France, Amphia Hospital in Breda, the Netherlands, and the Clinical Center of Serbia in Belgrade, Serbia. Professor Emmanuel Messas, a cardiologist at the Georges Popidou, will serve as the study’s principal investigator. Valvopulse precisely delivers pulsed, mechanical focused ultrasound to disrupt and soften the calcifications on aortic valve leaflets. The procedure is designed to restore valve mobility and enable the aortic valve to once again open widely –
immediately after the procedure.

Read More >

The Focused Ultrasound Foundation Newsletter

Our newsletter delivers updates for clinicians, researchers and patients. Sign up and stay on top of the rapid advancements of this innovative medical technology.

Sign Up  Read the Latest Issue

Read The Tumor  by John Grisham

From John Grisham, comes a story where today’s medical fiction could become tomorrow’s lifesaving reality.

Download a Free eBook or Audiobook

Contact Details

Call Us
Find Us
Focused Ultrasound Foundation
1230 Cedars Court, Suite 206 Charlottesville, VA 22903
Whitelist Instructions